TABLE 1.
Baseline characteristics among MESA participants with and without NAFLD (LSR<1)
| Liver-to-Spleen Ratio | |||
|---|---|---|---|
| No. (%) or mean (+/− SD) | ≥1 | <1 | p-value |
| N | 3342 | 696 | <0.001 |
| Age | 63 (11) | 61 (10) | 0.456 |
| Male | 1485 (44%) | 320 (46%) | <0.001 |
| Race | |||
| White | 1271 (38%) | 231 (33%) | 0.016 |
| Chinese | 319 (10%) | 79 (11%) | 0.146 |
| African-American | 1058 (32%) | 135 (19%) | <0.001 |
| Hispanic | 694 (21%) | 251 (36%) | <0.001 |
| Education | |||
| < High School | 592 (18%) | 173 (25%) | <0.001 |
| HS + non-college level | 1588 (48%) | 327 (47%) | 0.799 |
| College or more | 1148 (35%) | 193 (28%) | 0.001 |
| Smoking | 0.097 | ||
| Never | 1720 (52%) | 389 (56%) | 0.032 |
| Former | 1230 (37%) | 230 (33%) | 0.061 |
| Current | 379 (11%) | 74 (11%) | 0.592 |
| Body Mass Index (kg/m2) | 28.1 (5.2) | 31.1 (5.4) | <0.001 |
| Diabetes | 387 (12%) | 157 (23%) | <0.001 |
| Hypertension | 1529 (46%) | 370 (53%) | <0.001 |
| SBP | 127 (22) | 130 (21) | 0.001 |
| DBP | 70 (10) | 73 (10) | <0.001 |
| HTN Meds | 1274 (38%) | 309 (44%) | 0.002 |
| LDL | 118 (31) | 116 (31) | 0.162 |
| HDL | 52 (15) | 45 (12) | <0.001 |
| Triglycerides* | 105 [75, 152] | 154 [107, 209] | <0.001 |
| Lipid lowering meds | 540 (16%) | 122 (18%) | 0.379 |
| Coagulation Markers | |||
| CRP (mg/L)* | 1.79 [0.81, 1.87] | 2.94 [1.37, 6.28] | <0.001 |
| IL-6 (pg/mL)* | 1.23 [0.78, 1.87] | 1.52 [1.02, 2.37] | <0.001 |
| Waist circumference | 97.4 (13.7) | 105.7 (13.4) | <0.001 |
| Glucose | 95.7 (28.5) | 108.5 (39.2) | <0.001 |
*
median [IQR]
(Abbreviations: MESA: Multi-ethnic study of atherosclerosis, NAFLD: Non-alcoholic fatty liver disease)